Guillain-Barre syndrome is a rare but serious condition which needs urgent treatment in hospital to prevent it progressing.

The UK's medicines regulator has warned NHS healthcare staff about an increased risk of a condition affecting the nerves in ...

OVER 20 people developed a potentially paralysing illness after getting the respiratory syncytial virus (RSV) vaccine. The UK ...

The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...

It is not clear how AS01 might help lower the risk of dementia, but Oxford University said lab studies show that the adjuvant ...

Researchers found that older adults who received AS01-adjuvanted shingles or RSV vaccines had a significantly lower risk of ...

A new study from the University of Oxford has revealed a surprising benefit of the respiratory syncytial virus (RSV) vaccine: ...

A new study by the University of Oxford, published in the journal npj Vaccines, shows that a vaccine against respiratory ...

Frailty strongly predicts worse RSV outcomes in older adults, highlighting the need for targeted care as aging populations face rising infection risks.

This Abrysvo or Arexvy market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the ...

The GSK RSV vaccine Arexvy is not currently available on the NHS but may be available privately in the UK. Symptoms of Guillain-Barre syndrome can include tingling, numbness or pins and needles in ...